Binnopharm Group has broadened its range of products in the markets of Uzbekistan, Tajikistan, and Azerbaijan, acquiring registration certificates for nine of its products.
Regulatory certificates have been granted for the tablet forms (50mg+450mg and 100mg+900mg) as well as the gel form of drugs Venarus, Neobutin, and Retard in Uzbekistan. Products are manufactured at the site of Alium JSC in Obolensk, Moscow Region.
Kagocel and Bisoprolol-AKOS have obtained registration for distribution in Tajikistan. The drug in question has also obtained a regulatory certificate in Azerbaijan. Nearmedic Pharma has established drug production in the Moscow Region, while Biokom has done the same in Stavropol.
Expanding international expansion remains a strategic goal for Binnopharm Group. As stated by Aleksey Chupin, the Director of R&D and Registration at Binnopharm Group, the company’s continuous efforts to expand its product portfolios in the CIS countries have enabled them to be at the forefront of Russian drug manufacturers.
